

PREGNANCY OUTCOME IN EGYPTIAN PATIENTS WITH RHEUMATOID ARTHRITIS

Thesis

**Submitted for Partial Fulfillment Requirement of Master degree
in internal medicine**

Submitted by

Nagham Safwat Ebrahim Samy

M.B.B.CH

Supervisors

Prof Dr. Samah Abd El-Rahman EL Bakry

Professor of Internal Medicine and Rheumatology
Ain Shams University

Assist. Prof. Dr. Maryam Ahmed Abd El-Rahman

Assistant Prof of Internal Medicine and Rheumatology
Ain Shams University

Dr. Nermeen Samy Khalel

Lecturer of Internal Medicine and Rheumatology
Ain Shams University

*Faculty of Medicine
Ain shams University*

2019

Acknowledgement

First and foremost, I would like to thank great Allah for helping me to complete this work,

I will remain grateful to Prof. Dr. Samah Abd El-Rahman EL Bakry Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University , whose directions helped me to set my foot on the right track, and made the completion of this work possible. She has kindly helped me throughout this study.

Much gratitude is expressed to Dr. Maryam Ahmed Abd El-Rahman Assistant Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, for her very kind support, passion, help and careful supervision.

I would like to thank Prof. Dr. Rehab Mohamed Abd El-Rahman Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for her patient supervision, unlimited cooperation and great care throughout the work,

Also, I wish to express my deep gratitude to Dr. Nermeen Samy Khalef Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, for her generous support and sincere encouragement during the whole period of the study.

I am also thankful to all staff members and to my colleagues in the Rheumatology and Obstetrics departments for their help.

Last but not least, I would like to express my great gratitude to my dear loving family for their support and encouragement.

Nagham Safwat Samy

LIST OF CONTENTS

| Title | Page |
|---|------|
| LIST OF ABBREVIATIONS..... | i |
| LIST OF TABLES | v |
| LIST OF FIGURES | vii |
| I. INTRODUCTION..... | 1 |
| II. AIM OF THE WORK | 3 |
| III. REVIEW OF LITERATURE..... | 4 |
| Chapter (1) Rheumatoid arthritis | 4 |
| Chapter (2) Rheumatoid arthritis and pregnancy..... | 36 |
| IV. PATIENTS and METHODS..... | 67 |
| V. RESULTS..... | 72 |
| VI. DISCUSSION | 105 |
| VII. SUMMARY AND CONCLUSIONS | 114 |
| VIII. RECOMMENDATIONS..... | 116 |
| IX. REFERENCES..... | 117 |
| ARABIC SUMMARY | |

LIST OF ABBREVIATIONS

| Abbreviation | Full name |
|-----------------------------|---|
| 11 -HSD2 | : 11-hydroxysteroid dehydrogenase type 2 |
| ACPA | : Anti citrullinated protein antibodies |
| ACR | : American College of Rheumatology |
| ADA | : Adalimumab |
| ALT | : Alanine transaminase |
| Anti Carp antibodies | : Antibodies against carbamylated proteins |
| Anti-MCV | : Antibodies to citrullinated vimentin and mutated citrullinated vimentin |
| ASD | : Atrial septal defect |
| AST | : Aspartate aminotransferase |
| axSpA | : Axial sponyloarthritis |
| AZA | : Azathioprine |
| BHPR | : British Health Professionals in Rheumatology |
| BMI | : Body mass index |
| BSR | : British Society of Rheumatology |
| CBC | : Complete blood picture |
| CCP | : Cyclic citrullinated peptides |
| CDA1 | : Clinical disease activity index |
| CICs | : Circulating immune complexes |
| CNS | : Central nervous system |
| COX-2 | : Cyclooxygenase-2 |
| CPPD | : Calcium pyrophosphate dehydrate |
| CRP | : C-reactive protein |
| CS | : Cesarean section |
| CSs | : Corticosteroids |

| Abbreviation | Full name |
|---------------------|---|
| CVD | : Cardiovascular diseases |
| DAS 28 | : Disease Activity Score 28 |
| DHFR | : Dihydrofolate reductase |
| DMARDs | : Disease-modifying antirheumatic drugs |
| EAMs | : Extra-articular manifestations |
| EBV | : Epstein-Barr virus |
| ELISA | : Enzyme linked immunosorbent assay |
| ESR | : Erythrocytic sedimentation rate |
| ETA | : Etanercept |
| EULAR | : European League Against Rheumatism |
| FGR | : Fetal growth restriction |
| HCQ | : Hydroxychloroquine |
| HLA | : Human leukocyte antigen |
| IBD | : Inflammatory bowel disease |
| IFN | : Interferon |
| IFX | : Infliximab |
| IgG | : Immunoglobulin G |
| IgM | : Immunoglobulin M |
| IL-1 | : Interleukin-1 |
| IL-1Ra | : Interleukin-1 receptor antagonist |
| IL-2 | : Interleukin-2 |
| ILD | : Interstitial lung disease |
| IQR | : Interquartile range |
| JAC | : Jannus Kinase Inhibitors |
| JIA | : Juvenile idiopathic arthritis |
| LBW | : low birth weight |

| Abbreviation | Full name |
|---------------------|--|
| LEF | : Leflunomide |
| LUF | : Luteinized unruptured follicle syndrome |
| MBDA | : Multibiomarker disease activity |
| MCM | : Major congenital malformation |
| MCP | : Metacarpophalangeal joint |
| mHAQ | : Modified Health Assessment Questionnaire |
| MRI | : Magnetic resonance imaging |
| MTP | : Metatarso-phalangeal joint |
| MTX | : Methotrexate |
| NICU | : Neonatal intensive care unit |
| NSAIDS | : Non-steroidal anti-inflammatory drugs |
| PAG | : Pregnancy-associated globulin |
| p-ANCA | : Positive necrotizing crescentic glomerulonephritis |
| PG | : Prostaglandins |
| PIP | : Proximal interphalangeal joint |
| PIGF | : Placental growth factor |
| RA | : Rheumatoid arthritis |
| RF | : Rheumatoid factor |
| RV | : Rheumatoid vasculitis |
| SD | : Standard deviation |
| SDAI | : Simplified Disease Activity Index |
| sENG | : Soluble endoglin |
| sFlt-1 | : Soluble fms-like tyrosine kinase 1 |
| SGA | : Small for gestational age |
| SLE | : Systemic lupus erythematosus |

| Abbreviation | Full name |
|---------------------|---|
| SPSS | : Statistical package for Social Science |
| SS | : Sjogrens syndrome |
| SSZ | : Sulfasalazine |
| STNFRs | : Soluble tumor necrosis factor-alpha receptors |
| T2DM | : Type 2 diabetes mellitus |
| Th1 | : T helper cell 1 |
| TH2 | : T helper cell 2 |
| TNF-a | : Tumor necrosis factor-a |
| TNFI | : Tumor necrosis factor inhibitors |
| TTP | : Time to pregnancy |
| US | : Ultrasound |
| VSD | : Ventricular septal defect |

LIST OF TABLES

| Table | Title | Page |
|--------------------|---|-------------|
| Table (1): | The 2010 EULAR/ACR classification criteria for RA | 18 |
| Table (2): | Three of the principals of quantitative measures used to evaluate activity and severity of RA and the predefined threshold for remission, moderate, and high disease activity | 26 |
| Table (3): | TNF- α inhibitors agent | 32 |
| Table (4): | Non-TNFI Biologics | 33 |
| Table (5): | DAS 28 score interpretation | 68 |
| Table (6): | The demographic data of our RA patients | 73 |
| Table (7): | Descriptive data regarding the articular manifestation among RA patients | 74 |
| Table (8): | Extra articular manifestation among our RA patients | 75 |
| Table (9): | Disease activity assessment by DAS 28 ESR score, CDAI score and SDAI score among RA patients | 77 |
| Table (10): | M.HAQ score among RA patients | 80 |
| Table (11): | Obstetric history among RA patients | 81 |
| Table (12): | Natal and postnatal complication among RA patients | 82 |
| Table (13): | Drugs intake prior to conception among RA patients (retrospective from patients registry) | 83 |
| Table (14): | Comparison between RA patients and controls as regards obstetric history | 84 |
| Table (15): | Comparison between RA patients group and control group as regards natal and postnatal complications. | 86 |
| Table (16): | Correlation between average disease activities during pregnancy (assessed by DAS 28 ESR score) and obstetric data among RA patients | 90 |

| Table | Title | Page |
|--------------------|--|-------------|
| Table (17): | Comparison between patients used MTX (prior to conception) and patients who did not use it regarding obstetric history among RA patients | 93 |
| Table (18): | Comparison between patients using and not using Hcq during pregnancy regarding obstetric data among RA patients | 95 |
| Table (19): | Comparison between patients used leflunamide (prior to conception) and patients who did not use it regarding obstetric history among RA patients | 96 |
| Table (20): | Comparison between patients used corticosteroid during pregnancy and patients who did not use it regarding obstetric history among RA patients | 97 |
| Table (21): | Comparison between patients used NSAID (prior to conception) and patients who did not use it regarding obstetric history among RA patients. | 99 |
| Table (22): | Correlation between disease duration and obstetric data among the studied RA group | 100 |
| Table (23): | Correlation between average disease activity during pregnancy assessed by DAS 28 ESR score and obstetric history among RA patients | 102 |
| Table (24): | Correlation between obstetric history and drugs used among the studied RA group | 104 |

LIST OF FIGURES

| Figure | Title | Page |
|---------------------|--|-----------|
| Figure (1): | Immune pathway in rheumatoid arthritis | 7 |
| Figure (2): | Ulnar deviation and subluxation of the metacarpophalangeal joints of the left hand. Muscle atrophy is also evident in the dorsal musculature of both hands | 12 |
| Figure (3): | Plain X-ray of hands of rheumatic arthritic patients | 22 |
| Figure (4): | Erosions in multiple carpal bones and metacarpal heads detected by MRI | 22 |
| Figure (5): | 2016 EULAR recommendation for the management of rheumatoid arthritis | 35 |
| Figure (6): | Disease activity assessment by DAS 28 ESR score among RA patients | 79 |
| Figure (7): | Number of abortions in RA patients & controls | 85 |
| Figure (8): | Natal complications in RA patients & controls. | 88 |
| Figure (9): | Postnatal complications in new borns of RA patients & controls | 88 |
| Figure (10): | Mode of delivery in RA patients & controls | 89 |
| Figure (11): | Correlation between average disease activity during pregnancy (assessed by DAS 28 ESR score) and obstetric data among RA patients | 92 |
| Figure (12): | Correlation between average disease activity during pregnancy (assessed by DAS 28 ESR score) and complications of new borns of RA patients | 92 |
| Figure (13): | Correlation between MTX use (prior to conception) and number of abortions after diagnosis of RA among RA patients | 94 |

| Figure | Title | Page |
|---------------------|---|-------------|
| Figure (14): | Relation between corticosteroid use during pregnancy and low birth weight among RA patients | 98 |
| Figure (15): | Correlation between RA duration and number of total abortions among RA group | 101 |
| Figure (16): | Correlation between duration of RA and number of abortions after diagnosis of RA among RA group | 101 |
| Figure (17): | Correlation between average disease activity during pregnancy assessed by DAS 28 ESR and number of pregnancies after diagnosis of RA among RA group | 103 |
| Figure (18): | Correlation between average disease activity during pregnancy assessed by DAS 28 ESR score and number of abortions after diagnosis of RA among RA group | 103 |

INTRODUCTION

Rheumatoid arthritis (RA) is considered a chronic immune-mediated inflammatory disease which can cause significant disability, morbidity, and mortality. RA affects women three times more often than men, commonly in their childbearing years (*Kieran et al., 2018*).

Rheumatoid arthritis may adversely influence pregnancy through several mechanisms. The inflammatory process of RA may affect the placenta, leading to adverse birth outcomes for example low birth weight. RA disease activity may thus necessitate drug treatment to ensure a successful pregnancy outcome. At the same time, exposure to anti-inflammatory, immunosuppressive or biological drugs in utero may adversely affect pregnancy outcome. In recent years, RA treatment regimens have included earlier and more aggressive use of disease modifying drugs. In addition, lifestyle factors such as smoking is a risk factor for RA which can lead to preterm birth and small for gestational age (SGA) infants (*Norgaard et al., 2010*).

Also, fertility is compromised in women with rheumatoid arthritis (RA). Most of them have fewer children than they intended to have and they are more often nulliparous (*Jenny et al., 2017*).

Because in most women with RA antirheumatic treatment has to be adjusted before trying to conceive, a longer the time to pregnancy can result in a prolonged period with less controlled disease and consequently an increased risk for permanent damage to the joints . Female causes include anovulation, endometriosis, and unilateral or bilateral tubal occlusion. In 8–28% of subfertile couples, no specific cause is found during fertility assessments. They are referred to as couples with unexplained subfertility (*Jenny et al., 2017*).

AIM OF THE WORK

The aim of this study was to assess pregnancy outcomes in women diagnosed with RA compared with reference women from the general population with focus on mode of delivery, small for gestational age, preterm birth, perinatal death and congenital malformations.

REVIEW OF LITERATURE

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease, which affects mainly synovial joints, reducing life expectancy and quality of life. Although joint involvement is the most common feature of the disease with the typical symmetric tenderness and swelling of {metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, wrists and metatarsophalangeal (MTP) joints}, extra-articular manifestations, which reflect systemic involvement are common and include manifestations on the heart, skin, renal, eye, lung, gastrointestinal and nervous systems (*Xhaferi and Lamaj, 2015*).

Epidemiology

RA affects 0.5% to 1% of the population worldwide, with women 2 to 3 times as likely as men to be affected with the disease. Studies in industrialized countries show annual incidences between 5 and 50 per 100 000 with results varying based on case identification methods and geographical differences. RA is common in northern Europe and North America. Age at onset is usually between 30 and 70 . Evidence suggests that RA incidence may decline with disease onset shifting towards older age groups (*Kerola et al., 2015*).